| Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process C Bennett, N Vakil, J Bergman, R Harrison, R Odze, M Vieth, S Sanders, ... Gastroenterology 143 (2), 336-346, 2012 | 487 | 2012 |
| Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial JAZ Jankowski, J De Caestecker, SB Love, G Reilly, P Watson, S Sanders, ... The Lancet 392 (10145), 400-408, 2018 | 280 | 2018 |
| Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus Esophageal Adenocarcinoma Genetics Consortium, ... Nature genetics 44 (10), 1131-1136, 2012 | 209 | 2012 |
| Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor CR Haigh, SEA Attwood, DG Thompson, JA Jankowski, CM Kirton, ... Gastroenterology 124 (3), 615-625, 2003 | 201 | 2003 |
| Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus C Palles, L Chegwidden, X Li, JM Findlay, G Farnham, FC Giner, ... Gastroenterology 148 (2), 367-378, 2015 | 122 | 2015 |
| Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin A Varro, E Hemers, D Archer, A Pagliocca, C Haigh, S Ahmed, R Dimaline, ... Gastroenterology 123 (1), 271-280, 2002 | 66 | 2002 |
| The diagnosis of primary eosinophilic oesophagitis in adults: missed or misinterpreted? V Kanakala, CA Lamb, C Haigh, RW Stirling, SE Attwood European journal of gastroenterology & hepatology 22 (7), 848-855, 2010 | 52 | 2010 |
| Development and validation of a novel Barrett's oesophagus patient reported outcome measure (B-PROM) E Ratcliffe, J Britton, S Baines, N Prasad, R Keld, M Murgatroyd, ... EClinicalMedicine 72, 2024 | 1 | 2024 |
| Oracular Guidance on Clinical Management of Early Neoplastic Barrett's Esophagus H Curtis, DA Corley, KK Krishnadath, TW Rice, N Vakil, D Hewin, D Loft, ... Gastroenterology 143, 282-284, 2012 | | 2012 |
| Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer? Reply CR Haigh, C Kirton, DM Pritchard, A Varro, R Dimaline, SEA Attwood, ... GASTROENTEROLOGY 125 (6), 1912-1913, 2003 | | 2003 |
| Gastrin-induced hyperproliferation in Barrett's esophagus-Reply CR Haigh, CM Kirton, DM Pritchard, A Varro, R Dimaline, SEA Attwood, ... GASTROENTEROLOGY 125 (6), 1921-1922, 2003 | | 2003 |
| Can Proton Pump Inhibitors Be Blamed for the Rising Incidence of Esophageal Cancer?[2](multiple letters) M Younes, CR Haigh, C Kirton, DM Pritchard, A Varro, R Dimaline, ... | | 2003 |
| Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer? Authors' reply M YOTJNES, CR HAIGH, C KIRTON, DM PRITCHARD, A VARRO, ... Gastroenterology 125 (6), 1912-1913, 2003 | | 2003 |
| Amidated gastrin induces proliferation via the cholecystokinin type 2 (CCK2) receptor in Barrett's oesophagus CR Haigh, SEA Attwood, DG Thompson, CM Kirton, DM Pritchard, A Varro, ... JOURNAL OF PHYSIOLOGY-LONDON 543, 50P-50P, 2002 | | 2002 |
| Identification by gene array of plasminogen activator inhibitor-2 (PAI-2) as a novel target of gastrin in hypergastrinaemia A Varro, E Hemers, D Archer, A Pagliocca, C Haigh, S Ahmed, R Dimaline, ... GUT 50, A35-A35, 2002 | | 2002 |
| Plasminogen activator inhibitor-2 (PAI-2) is a novel target of gastrin in hypergastrinemia GJ Dockray, E Hemers, D Archer, A Pagliocca, C Haigh, R Dimaline, ... GASTROENTEROLOGY 122 (4), A84-A84, 2002 | | 2002 |
| PPI, Aspirin und Prävention von Barrett-Neoplasien–Wie behandeln wir jetzt unsere Barrett-Patienten? JAZ Jankowski, J de Caestecker, SB Love, G Reilly, P Watson, S Sanders, ... | | |
| PPI, Aspirin and Prevention of Barrett’s Neoplasia–How Do We Treat Our Barrett Patients Now? JAZ Jankowski, J de Caestecker, SB Love, G Reilly, P Watson, S Sanders, ... | | |
| Available at http://clok. uclan. ac. uk/16074 C Palles, L Chegwidden, X Li, JM Findlay, G Farnham, F Castro Giner, ... | | |
Stephen AttwoodProfessor of Surgery Durham University UKVerified email at nhct.nhs.uk
